Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells by Grillberger, Leopold et al.
Biotechnology
Journal
DOI 10.1002/biot.200800241 Biotechnol. J. 2009, 4, 186–201
186 © 2009 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
1 Introduction
Recombinant therapeutic proteins can be pro-
duced in microorganisms,plant cell cultures,insect
and mammalian cell lines, or transgenic animals.
Over 165 biopharmaceutical products have been
approved globally [1] and the vast majority of these
are proteins.Protein therapeutics were initially ex-
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tracted from the tissues or blood of humans or oth-
er animals and in some cases, human plasma-de-
rived products still remain the only therapeutic op-
tion (e.g., intravenous immunoglobulin). A major
benefit of recombinant proteins is that they serve
as a platform for the development of more ad-
vanced products that are engineered for an im-
proved therapeutic profile, such as enhanced safe-
ty, lower immunogenicity, increased half-life and
improved bioavailability.
A number of recombinant therapeutic proteins,
including recombinant human insulin, are pro-
duced in microbial expression systems established
using bacteria or yeast. However, the production of
larger, more complex proteins often requires ex-
tensive post-translational modifications, particu-
larly glycosylation. Most microbial systems cannot
perform all of the modifications necessary for
proper protein structure and function. Instead,
mammalian expression systems have been the tra-
ditional approach for the large-scale manufacture
of therapeutic proteins which require these critical
post-translational modifications.An additional ad-
vantage of these mammalian cell systems is that
the recombinant proteins are secreted into the me-
dia in their natural form.E.coli-expressed proteins,
on the other hand, mostly accumulate in a highly
denatured form within the cell as inclusion bodies
and require renaturation later in the manufactur-
ing process [2]. About 60-70% of all recombinant
protein therapeutics are produced in mammalian
cells, primarily Chinese hamster ovary (CHO) cells
[3]. CHO cells have many characteristics that have
made them the most widely used mammalian host
system. In addition to ease of manipulation and
other characteristics preferred for large-scale pro-
duction of proteins,proteins produced in CHO cells
have a proven safety profile in humans and these
proteins also have glycosylation patterns similar to
that of human proteins [4].Advances in modulating
the glycosylation patterns of some yeast strains
(e.g., P. pastoris) may lead to an alternative, non-
mammalian cell system in the future [5] but cur-
rently, mammalian cells remain the primary vehi-
cle for  large-scale production of recombinant ther-
apeutic glycoproteins.
Hemophilia A is an X-linked coagulation disor-
der resulting from mutations in the coagulation
factor VIII (FVIII) gene. Patients with severe he-
mophilia rely on exogenous factor VIII therapy to
prevent or counter the debilitating and potentially
life-threatening consequences of prolonged bleed-
ing [6]. Driven primarily by the need for improved
safety [7], factor VIII replacement therapy has
evolved from the initial use of whole blood, citrat-
ed plasma and cryoprecipitate.The first step in this
evolution was the switch to plasma-derived puri-
fied FVIII concentrates in the 1970s, followed by
recombinant FVIII concentrates starting in 1992,
and finally to animal- and human-plasma free re-
combinant FVIII starting in 2003 (Fig.1).In the ab-
sence of a cure for hemophilia, the development of
plasma-free (PF) recombinant FVIII eliminated
the risk of blood-borne infections during lifelong
therapy.
Additives in biopharmaceutical manufacturing
can be derived from a variety of human or animal
sources, including blood, milk, bones, hides, ten-
dons, hair, skin, or pancreas (Fig. 2). The main
threat, however, is associated with the use of blood
or serum-derived proteins. Traditionally, cells are
grown in a serum-based medium rich in growth
factors and supplements, without which therapeu-
tic proteins could not be produced on a commercial
scale. Serum, however, presents many challenges
for biopharmaceutical manufacturing. Viral out-
breaks and the mad cow disease epidemic high-
lighted the risk of pathogen transmission through
serum, and concerns arose over the safety of re-
combinant proteins produced by cells grown in the
Figure 1. Evolution of safety measures
in factor VIII replacement therapy.
Boxes above the arrow highlight
pathogens that were transmitted to
hemophilia patients through blood-
derived additives. Boxes below the
arrow represent the processing steps
that enabled higher purity products to
be developed, leading to plasma-free
recombinant factor VIII. NAT, nucleic
acid amplification testing.
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presence of ingredients sourced from humans or
animals. In addition, the recombinant protein pro-
duction process can be encumbered by the re-
quirement for serum, due to serum’s high protein
content and variability, and the inclusion of serum
can potentially increase the immunogenicity of
certain products.This review will discuss the driv-
ers behind the development of the plasma-free
process,the response by regulatory and physicians’
organizations, and the advances that have enabled
the elimination of serum-derived additives from
the manufacturing of recombinant therapeutic
proteins.
Figure 2. Potential sources of human or
animal components that have been used
in the manufacturing of recombinant
therapeutic proteins. These additives can
be derived from a number of tissues and
have been used in cell culture medium
during production and/or downstream
formulation.
Figure 3. Examples of the most common-
ly known emerging pathogens from the
last three decades. HIV, HCV, vCJD, and
WNV have been shown to exhibit blood-
borne transmission.
In 25 years,
nearly 65
million people
were infected
with HIV. In
2007, ~33
million people
living with HIV
[UNAIDS]
3.2 million
cases in the
US [CDC]
1995 – mid 2007,
202 cases
worldwide.
December 2003
– April 2007, 4
cases of blood
transfusion
transmission
[FDA/CBER]
Between 1 and 2
million cases in
the U.S. 80% of
infected people
are totally
asymptomatic
[CDC].
Transfusion
transmission
has been
reported [CDC]
November
2002 – July
2003, 8,096
cases; 774
deaths
[WHO]
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2 Drivers for the development of a PF 
manufacturing process
2.1 Threat of infectious diseases: Lessons from the
past and outlook for the future
Serum and its components are routinely used in
cell culture media to support the growth of cell
lines.Serum components such as albumin and gel-
atin are commonly used as stabilizers in the for-
mulation of recombinant therapeutic proteins (Fig.
2).The past several decades,however,have brought
to light the serious risks associated with the use of
animal or human components in the manufacture
of therapeutics, most notably the transmission of
infectious agents (Fig. 3). This risk is amplified
when human and/or animal-derived materials are
used at multiple steps in the manufacturing
process,or when a treatment modality requires re-
peated administrations of such a product.
2.2 Risk of virus transmission
Many emerging blood-borne infectious agents are
characterized by long-lasting, silent carrier states
in which the pathogen is present in the circulation
without causing obvious or noticeable symptoms
[8].Blood or plasma collected during this asympto-
matic latent phase can be highly infectious.This is
exemplified by human immunodeficiency virus
(HIV) which has infected nearly 65 million people
worldwide.An estimated 33 million people are cur-
rently infected with HIV, yet the vast majority of
these individuals are unaware of their HIV+ status
[http://www.unaids.org/en/KnowledgeCentre/HIV
Data/GlobalReport/2008/].
The coronavirus which is responsible for severe
acute respiratory syndrome (SARS) is another ex-
ample of an emerging human pathogen resulting
from zoonotic transmission [9]. Unlike HIV, this
coronavirus caused a severe but short epidemic fol-
lowing adaptation to its new human host. Many
epidemiologists predict similar types of outbreaks
from emerging viruses in the future,with the great-
est threat to biopharmaceutical manufacturing be-
ing the non-lipid enveloped (NLE) viruses such as
circoviruses. Circoviruses, which include torque-
tenovirus (TTV) and torque-tenominivirus (TTMV),
are the smallest of all known mammalian NLE
viruses and they cannot be eliminated by nanofil-
tration [10].
Historically, the risk of pathogen transmission
was of particular concern in the manufacture of
blood-derived coagulation factors. In the early
1980s, plasma-derived factor-replacement prod-
ucts used to treat hemophilia were found to be con-
taminated with HIV and hepatitis B and C viruses
(Fig. 1). By 1984, up to 78% of US patients with he-
mophilia were infected with HIV and 74-90% were
infected with HCV [11]. Consequently, the life ex-
pectancy for patients with hemophilia in the US
decreased from 68 years in the 1970s to 49 years in
the 1980s.
Subsequently, new donor screening methods as
well as virus- inactivation and removal measures
have been adopted. These methods have further
improved the safety of plasma-derived or plasma-
containing products such that no new cases of HIV,
HBV, or HCV transmission from plasma or recom-
binant therapies have been reported in the US
since 1997 [www.hemophilia.org]. However, sol-
vent/detergent,which is the most common virus in-
activation technique used in the preparation of
plasma-derived products, is mainly effective
against lipid-enveloped viruses, such as HIV, HBV,
HCV,HTLV (human T-cell lymphotropic virus) and
WNV (West Nile virus). NLE viruses, such as par-
voviruses, enteroviruses and circoviruses, are re-
sistant to inactivation via solvent/detergent treat-
ment and to some degree against heat and radia-
tion as well [12]. Parvovirus B19 (B19V) and two
Table 1. Currently available recombinant factor VIII concentrates. Shaded boxes denote the presence of human-or animal-derived serum components
Components in cell culture medium Primary stabilizer in formulation
First Generation
Recombinatea) Bovine serum proteins Human Serum Albumin
Second Generation
ReFactob) Human Serum Albumin Sucrose
Kogenate FSa)/Helixate FSa), c) HPPS (Human Plasma Protein Solution) Sucrose
Third Generation
Advatea) Non human- or animal-derived Trehalose
Xynthab), d) Non human- or animal-derived Sucrose
a) Full-length FVIII.
b)B-domain deleted FVIII.
c) FS in the US, NexGen in Europe.
d) US only. Contains E. coli-expressed insulin.
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genotypes of parvovirus PARV4, have been found
as contaminants in plasma-derived factor VIII con-
centrates [13, 14]. Thus, the risk of viral infection
remains when plasma-derived and plasma-con-
taining recombinant FVIII products are used [15,
16].
The cloning of the FVIII gene in 1984 [17,18] led
to the development of the first recombinant FVIII
therapy (Recombinate, Baxter), which was initially
licensed in the US in 1992. Recombinant FVIII
products are now classified into three generations
(as defined by MASAC, the Medical and Scientific
Advisory Council of the National Hemophilia
Foundation) based on the degree of elimination of
plasma and albumin from production and/or for-
mulation steps, as outlined in Table 1 [MASAC
#182].First generation products use plasma and/or
albumin during both the cell culture process and
the final formulation steps, while 2nd generation
products use serum proteins during the cell culture
process only. These early recombinant products
were effective in reducing the risk of pathogen
transmission but the presence of serum compo-
nents was still a concern. Indeed, one first genera-
tion recombinant FVIII product containing human
serum albumin (Kogenate,Bayer) was suggested as
a source of B19V transmission [19]. Moreover, the
presence of human or animal proteins in thera-
peutic products potentially puts patients at risk of
contracting novel infections, including those
caused by not-yet detectable pathogens. These
concerns prompted MASAC to issue recommenda-
tion #106: “Manufacturers of the recombinant
products are strongly encouraged to avoid using
human and animal proteins in manufacturing their
products.” Only by completely removing plasma
proteins from the cell culture and final formulation
processes could the risk of infectious disease trans-
mission from recombinant products be totally
eliminated. Such plasma-free recombinant pro-
teins were classified as third generation products.
The first recombinant FVIII product that fit
these criteria,(Advate,Baxter),became available in
the US in 2003 and in the EU in 2004.Advate is pro-
duced in CHO cells that were adapted to grow in a
medium free of human- and animal-derived addi-
tives.Specifically,the serum- and protein-free syn-
thetic minimal medium used for producing Advate
contains ultrafiltered soy bean peptides with an av-
erage molecular weight of < 500 Daltons,along with
sugars, salts and other components which are
added to further nourish the CHO cells.The FVIII
is then purified through a series of chromatogra-
phy steps,including an immunoaffinity chromatog-
raphy process utilizing a monoclonal antibody pro-
duced from hybridoma cells grown for more than
30 generations in a plasma-free environment. Ad-
vate is then stabilized with trehalose [20]. There-
fore, since Advate is never exposed to plasma, the
risk of transmitting known and emerging blood-
borne pathogens is eliminated. Current manufac-
turing processes address disease threats that have
endangered the blood supply in the past, but there
are others for which donated plasma is not rou-
tinely screened [12]. For example, human her-
pesvirus 8, the causative agent for Kaposi’s sarco-
ma, has been shown to be transmitted through
blood and blood products [21, 22]. Although the
lipid membranes of  enveloped viruses generally
render them susceptible to inactivation by combi-
nations of solvents and detergents, the transmis-
sion of lipid-enveloped WNV via blood transfusion
[http://www.cdc.gov/mmwr/preview/mmwrhtml/
mm5313a1.htm] still raises new concerns about the
safety of the blood supply. Therefore, due to the
fact that solvent/detergent and nanofiltration
techniques are not 100% efficient against all
pathogens, plasma components need to be com-
pletely removed from the manufacturing process in
order to eliminate the risk of pathogen transmis-
sion through blood compo-nents.
2.3 Risk of transmissible spongiform 
encephalopathies (TSEs)
Prions are self-replicating infectious proteins that
cause currently untreatable and fatal neurodegen-
erative disorders. The detection of a new strain of
prions in humans in the 1990s prompted significant
changes in regulatory requirements for biophar-
maceutical manufacturing and in public health
policy. Consumption of meat contaminated with
bovine spongiform encephalopathy (BSE) caused
an outbreak of variant Creutzfeldt-Jacob disease
(vCJD) in the United Kingdom in 1996 [23, 24]. As
of September 2008, 206 primary cases of vCJD had
been reported in 11 countries,including the UK,US
and France [http://www.cjd.ed.ac.uk/vcjdworld.
htm]. Unlike cases of classic CJD, the prion that
causes vCJD is found in higher concentrations in
lymphoid tissues, and therefore presents a poten-
tial threat of transmission through blood and plas-
ma [25].
Indeed, four transfusion-transmitted cases of
vCJD have been reported [http://www.hpa.org.uk/
infections/topics_az/cjd/vCJDBloodDonors.htm,
26, 27]. In each confirmed case, the patient had re-
ceived red blood cell products from donors who lat-
er developed vCJD.The latest case reported by the
UK Health Protection Agency described an indi-
vidual who was diagnosed with vCJD nine years af-
ter receiving a blood transfusion from an asympto-
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matically infected donor. None of the four cases of
transfusion-transmitted vCJD transmission have
been associated with plasma-derived factor con-
centrates. No cases of vCJD transmission via blood
transfusion have been reported in the US. Howev-
er, the potential for vCJD transmission via plasma
products cannot be excluded yet [28]. A nine year
study in sheep [29] demonstrated that two different
TSE agents (BSE and scrapie) have unexpectedly
high rates of transmission through blood transfu-
sion, with relatively short and consistent incuba-
tion periods. These experiments suggest that the
infectivity titers in the blood are quite high, and
that blood transfusion represents an efficient route
of transmission for prions.
Adding to the concerns,prions are highly resist-
ant to physical/chemical inactivation and virus-re-
moval methods do not specifically target them [30].
Additionally, there is no way to detect prions in
plasma donors who may have  early stage, pre-
symptomatic infections. Epidemiologic models
generated from vCJD patients predict protracted
preclinical disease states and incubation times that
may exceed 50 years in individuals with certain
genotypes [31].
Iatrogenic transmission of prions has occurred
in patients who received human-derived pituitary
hormones such as human growth hormone (hGH)
and gonadotropins [32, 33]. CJD was transmitted to
over 160 recipients of cadaveric pituitary hGH [33-
36] prior to its withdrawal in most countries in
1985. Similarly, cadaveric pituitary-derived go-
nadotropins used to treat infertile women prior to
1985 were associated with iatrogenic transmission
of CJD [32, 37, 38]. Cadaveric pituitary hGH has
since been replaced with microbially-produced re-
combinant GH and recombinant gonadotropins
(CHO expressed) such as rhFSH have been in use
since the the mid-1990s.
vCJD is caused by a human-adapted form of the
prion responsible for BSE. Unlike other prions, the
adapted BSE prion has infected multiple species in
addition to humans [39], which suggests the possi-
bility that  additional emerging diseases may result
from transmission of prions not currently known to
infect humans [40]. One such transmissible prion
disease is Chronic Wasting Disease (CWD),which
affects elk and deer and potentially poses new
challenges to both animal and human health [41,
42]. Removal of all animal- or human-derived raw
materials or additives from biopharmaceutical
manufacturing eliminates the threat of infectivity
by known and other, yet unknown prions.
2.4 Unreliability and heterogeneity of serum and
raw source materials
With the discovery of any new infectious agent in
humans, the safety of the blood supply is re-
assessed, often resulting in expanded donor defer-
ral or further screening recommendations.The in-
creased exclusion of donors threatens the adequa-
cy of the blood supply and its derivatives, increas-
ing the risk of shortages [43]. This impacts the
availability of serum and of plasma- or serum-de-
pendent products and additives.
To further compound the issue, all sera used in
the manufacture of biopharmaceuticals is an unde-
fined mixture of individual donor sera, and there-
fore varies in composition from one lot to the next
[44]. Consequently, products extracted from differ-
ent pools of sera are also heterogeneous.Such vari-
ability imposes the requirement for additional
quality assurance steps in the manufacturing
process, which can negatively impact productivity
and operating costs [44,45].Since the manufacture
of recombinant plasma-free products does not re-
quire plasma-derived ingredients, PF technology
not only resolves the safety issues but also enables
manufacturers to deliver large quantities of these
proteins independent of the global plasma supply.
Concerns about safety, process consistency,
product performance, regulatory compliance and
reliability of supply prompted many biologics man-
ufacturers to progress from the use of serum to the
use of serum-free cell culture media.The next step
in the progression was to use animal-free media
and ultimately the switch was made to a protein-
free, completely synthetic, chemically defined me-
dia. Development of serum-free media is generally
difficult and must be individually tailored for each
process and cell line. In fact, even different clones
of a given cell line, like CHO cells, may require dif-
ferent formulations for optimal growth [46]. Addi-
tionally, the shift away from serum often comes
with the trade-off of reduced yields. Various sup-
plements are currently used to mimic the effects of
serum in promoting cell viability and optimal pro-
ductivity, including protein hydrolysates derived
from yeast, soy and wheat [47].These hydrolysates
contain amino acids, peptides, carbohydrates, vita-
mins and essential elements, and are ultrafiltrated
to remove endotoxin, residual proteins and con-
taminants, and to ensure a consistent average mo-
lecular weight.
The three most relevant components in serum
are albumin, insulin and transferrin.Traditionally,
bovine serum albumin (BSA) has been added to
serum-free medium as a lipid transport system, a
source of intermediary metabolites, and as a pro-
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tective agent against shear forces and oxidation
[48, 49]. Recombinant animal-free human albumin
is now commercially available for cell culture, as is
recombinant human insulin (produced in E. coli
and yeast), and E.coli expressed recombinant
human insulin-like growth factor. Similarly, yeast-
derived,animal-free recombinant human transfer-
rin is on the market [49]. These supplements are
among a growing list of animal-free reagents, sup-
plements and enzymes that are being commercial-
ized to support plasma-free mammalian cell cul-
ture.
Other advances have been made in generating
cell lines that are less dependent on sera-derived
components. Examples include CHO cells engi-
neered to produce their own transferrin and/or in-
sulin-like growth factor-I [50] and CHO cells that
co-express von Willebrand factor (vWF) along with
FVIII. vWF serves as a carrier for FVIII in plasma
and is thought to have a stabilizing effect on FVIII.
The co-expression of vWF with FVIII leads to in-
creased accumulation of FVIII activity in the ab-
sence of serum in the growth medium [51].
Beyond the production phase, serum-derived
components have traditionally been used to ad-
dress challenges associated with the formulation of
protein therapeutics. Recombinant therapeutic
proteins are required to be stable,with a significant
shelf life and good bioavailability. These desired
characteristics  present a challenge for product for-
mulation because therapeutic proteins have com-
plex tertiary structures and are often up to 1000
times larger than standard small molecule drugs.
Therefore,because proteins are often sensitive to a
wide range of factors such as temperature,pH,sur-
face adsorption and salt concentration, they are
typically formulated with a mixture of excipients to
ensure stability. These excipients include sugars,
polyols,amino acids,polymers and often,serum al-
bumin. In most cases, the final material must then
be lyophilized to avoid loss of activity during stor-
age.
For liquid formulations, it is frequently neces-
sary to prevent protein denaturation at the air-liq-
uid interface, and non-ionic detergents, such as
polysorbate, are typically used for that purpose. In
addition, it is often the case that the recombinant
protein is required in very small therapeutic doses
and can be denatured by surface adsorption to
glass vials.To prevent this issue,bulking agents like
carbohydrates (e.g., sucrose), or proteins such as
human serum albumin (HSA) or animal-derived
gelatin are added in excess of the active protein.As
a formulation excipient, HSA has an excellent sta-
bility and an acceptable safety profile [52, 53], and
along with gelatin, was traditionally among the
most commonly used excipients.However,as is the
case with all plasma-derived products, the risk of
pathogen transmission could not be eliminated.
Additionally,HSA exhibits structural heterogeneity
and batch-to-batch variability; its pharmacopoeial
purity requirement is only ≥ 96%, with the unde-
sired components being a mixture of polymers of
HSA and other contaminating plasma proteins re-
maining from the purification process [54]. Such
concerns prompted manufacturers to switch to
sugar-based final formulations and to develop a re-
combinant, plasma-free albumin produced in Sac-
charomyces cerevisiae for use as a stabilizer in bio-
pharmaceutical manufacturing [55]. Similarly,
Pichia pastoris yeast was engineered to produce re-
combinant animal-free gelatin, which presents  a
reduced risk of allergic responses compared to tis-
sue-derived substances [56, 57].
PF manufacturing requires the elimination of
plasma derivatives in every step of the process (Fig.
4), and proper post-production testing to ensure
that the product has not been compromised due to
stress on the protein-producing cells, which can
lead to an aberrant expression profile.The individ-
ual steps of the plasma-free production process in-
clude: (i) Development – Selection of a cell line,
transfection of cells and establishment of viable
cell banks that can yield high protein output in
serum-free medium (SFM), as well as  retain via-
bility and productivity after cryopreservation un-
der serum-free conditions.This requires an exten-
sive process of weaning and adaptation of the cells;
(ii) Upstream processing – Production of a protein
that is stable in animal-free cell culture medium;
(iii) Downstream processing – Purification of the
protein without the addition of plasma proteins;
(iv) Final formulation – Formulation of the product
without albumin or animal-derived additives; (v)
Testing – Rigorous testing to assure the safety and
efficacy of the PF product in a pre- and post-mar-
keting setting and to ensure that conformation/in-
tegrity of the molecule has not been compromised.
2.5 Improving clinical outcomes through 
plasma-free therapeutics
Most recombinant human proteins have been
shown to be immunogenic [58], although the anti-
body responses they generate are generally vari-
able and of low titer.However,these antibodies can
inhibit drug efficacy and cause life-threatening
complications when directed against either en-
dogenous self-proteins or exogenous therapeutic
proteins [59].The production of antibodies against
recombinant proteins is influenced by several fac-
tors, including structural properties of the protein,
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formulation, dose, route of administration, pres-
ence of impurities and the formation of aggregates
[60]. For example, high molecular weight complex-
es formed between rhIFN-α2 and HSA have been
linked to the formation of neutralizing antibodies
against the interferon molecule [59].This prompt-
ed researchers to develop albumin-free formula-
tions [61] in which HSA is replaced by other excip-
ients that can prevent oxidation, adsorption and
aggregation.A new formulation of IFN-β1a [RNF or
Rebif New Formulation, EMD Serono] was ap-
proved in Europe in August 2007 for the treatment
of relapsing forms of multiple sclerosis. RNF is
HSA-free and is produced by a CHO cell line in
serum-free culture medium [62]. Overall results
from a phase IIIb study suggest that RNF has im-
proved local tolerability and immunogenicity com-
pared with a historical study of the original formu-
lation [63],and the authors attribute these benefits
largely to the absence of serum components (HSA
and FBS) from the preparation.
Optimizing the clinical outcomes following
treatment with biopharmaceuticals is an issue of
special relevance to immune-compromised pa-
tients struggling with chronic diseases. Repeated
infusions over an extended period or over the life-
time of the patient increase the cumulative risk of
pathogen transmission. Therapeutic monoclonal
antibodies (mAb) have presented an innovative ap-
proach to the treatment of illnesses in which the
immune system may be compromised,such as can-
cer, autoimmune diseases and inflammatory disor-
ders [64]. Successive waves of technology have ad-
vanced mAb development from murine antibodies
to chimeric, humanized antibodies and finally to
fully-human antibodies. mAb manufacturing is
trending towards the adaptation of cell lines to
serum-free media, along with the removal of ani-
mal components from the purification and formu-
lation processes [45, 65-67]. One of the first exam-
ples of this trend is the tumor necrosis factor alpha
(TNFα) antagonist,which is approved for the treat-
ment of several autoimmune diseases including
rheumatoid arthritis and inflammatory bowel dis-
ease.The TNF antagonist has evolved from being a
chimeric mAb produced from cells grown in media
containg serum components (Remicade; Centocor)
to a fully human anti-TNFα mAb that is plasma-
free in both its manufacturing and formulation
(Humira;Abbott). Since TNF plays a critical role in
Figure 4. General scheme for commercial
development and production of a plas-
ma-free recombinant therapeutic protein.
In every step of the manufacturing
process, animal- or human-derived addi-
tives are replaced by plant-based or syn-
thetic moleculesa).
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modulating the inflammatory immune response,
patients treated with TNF antagonists are at special
risk for serious infections, which further empha-
sizes the need for such therapies to be completely
pathogen-free. In preventive therapies such as
vaccines, minimizing the risk of pathogen trans-
mission is also of paramount importance since vac-
cines are typically administered to large numbers
of children and elderly individuals.Animal protein-
free technology has been applied in the develop-
ment of pandemic and seasonal  influenza vac-
cines, in which embryonated  egg-based technolo-
gy is currently being replaced by mammalian cell
lines grown in  serum-free, protein-free medium.
Examples include the Vero cell-based H5N1 pan-
demic mock-up vaccine that has completed pre-
clinical development and is awaiting licensure
(Baxter) and a new MDCK cell-based seasonal in-
fluenza vaccine that was recently licensed in Eu-
rope (Optaflu; Novartis).
In the aftermath of the vCJD outbreak in the UK,
and with the recognition that prions can be trans-
mitted through blood,access of potentially infected
patients to dental and surgical care was impacted
[68].The UK government required the quarantine
of equipment and procedure rooms used on pa-
tients who were at risk of having contracted vCJD
from infected donors, including hemophilia pa-
tients who received plasma-derived factor concen-
trates.The prohibitive logistics and cost of dedicat-
ing equipment for at-risk patients may have made
hospitals and dental providers less likely to offer
standard services to these patients [68]. Problems
such as these can be mitigated by providing previ-
ously untreated patients with products that have
been manufactured without the addition of animal-
derived components.Such products are not only an
obvious choice for young, previously-untreated
and unexposed patients,but should also be consid-
ered for patients with existing infections (such as
HIV, HBV, or HCV) who must be concerned about
the introduction of additional pathogens, which
could further complicate a pre-existing infection
[69].
Another important factor to consider is that the
fear of exposure to potential pathogens in serum-
containing therapeutics may cause some patients
to forgo prescribed treatment. The availability of
products with no risk of pathogen transmission
may improve patient compliance, leading to better
treatment outcomes and improved quality of life.
3 Response from regulatory agencies and
physicians’ organizations
Assuring the safety of recombinant therapeutic
proteins is a primary concern of regulatory agen-
cies, provider organizations and manufacturers.
When alternatives to human- or animal-derived
materials do not exist, the best measures available
to assure product safety are to control the source of
the raw material,test raw material for possible con-
tamination by infectious agents,implement various
virus-inactivation and removal steps, and test the
end products to confirm absence of pathogens.
Following the BSE outbreak,strict requirements
were imposed on manufacturers of biologics and
medical devices regarding the country of origin for
bovine-derived material used in manufacturing
[http://www.fda.gov/cber/bse/bse.htm]. Drug com-
panies were forced to find alternatives as the list of
countries provisionally free of mad cow disease
dwindled. The list of restricted countries was up-
dated in 1998 to include not only those countries
where BSE was known to exist, but also countries
where no cases of BSE had been identified but
which were considered by the US Department of
Agriculture to have less restrictive import require-
ments than the US, and/or independent surveil-
lance. For biologics manufacturers, CBER (Center
for Biologics Evaluation and Research) now re-
quires that manufacturers provide detailed infor-
mation on the cell culture history, isolation, media,
identity and pathogen testing of cell lines used in
the production of biological products. Additional
source control measures include expanded human
donor screening and deferral guidelines. However,
safety regulations set forth by governments vary
between countries, and these variations are com-
pounded by donor screening policies that may dif-
fer even within the same country.
As noted by the US Centers for Disease Control
and Prevention (CDC), previous testing of source
material was inadequate due to the routine failure
of serologic screening to detect newly infected
donors in the pre-seroconversion phase of infec-
tion.This remains the single greatest risk of trans-
fusion-transmitted viral infections [24]. More sen-
sitive tests have been instituted, such as PCR-
based nucleic acid amplification testing (NAT), in-
cluding minipool NAT and single donor testing (ID
NAT). For HIV and HCV, NAT is expected to short-
en the lag time, during which infection cannot be
detected,from 22 to 12 days for HIV and from 70 to
14 days for HCV; but NAT is not able to completely
eliminate the lag time [24]. Donated blood is rou-
tinely tested for 6 pathogens:HBV,HCV,HIV-1 and
-2,HTLV-I and -II,Syphilis and WNV (when appli-
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cable). NAT is used to detect HIV, HCV, and WNV.
As new pathogens emerge, new tests are continu-
ally developed and implemented, such as the test
for Trypanosoma cruzi,the agent of Chagas disease
[70].
Methods for the inactivation and removal of
viruses from blood products first evolved in re-
sponse to the HIV epidemic in hemophilia A pa-
tients and became standard practice by the mid-
1980s [71]. These methods include pasteurization,
vapor heating, low pH, solvent/detergent treat-
ment, separation/purification techniques (such as
ion-exchange and immunoaffinity chromatogra-
phy) and nanofiltration.These steps have helped to
significantly reduce the frequency of infections
originating from the blood supply, especially for
those pathogens for which screening is also per-
formed. However, the risk from novel or emerging
pathogens must be taken seriously [72] and,as not-
ed by the CDC,“in order to protect the safety of the
blood supply and blood-derived therapies, it must
be recognized that new pathogens will continue to
emerge”[73].UK health officials withdrew all blood
and blood products obtained from donors in which
vCJD was subsequently detected, and today, all
plasma used in the UK to produce therapeutics is
imported. The UK is among many countries (in-
cluding Australia,New Zealand,Denmark,Ireland,
Canada and Japan) that are switching to recombi-
nant products as a standard for the treatment of
hemophilia A, and regulatory agencies and physi-
cians’ organizations in North America and Europe
have prompted drug and device manufacturers to
find alternatives to human and animal raw materi-
als and additives whenever possible (Table 2).The
FDA and the International Conference on Har-
monisation, which develops guidelines for the reg-
ulatory bodies of the European Union, Japan and
the US, have provided documents guiding the
sourcing,characterization and testing of raw mate-
rials derived from humans or animals, as well as
guiding the evaluation of protein therapeutics for
the presence of viruses [79-82].The objective is to
avoid transmission of adventitious agents, an issue
that would not exist if animal-free substances were
used in the manufacturing process.Because of reg-
ulatory concerns about serum and other animal-
derived components, the same product can be
manufactured in different formulations depending
on the regulatory requirements of the country in
which it is distributed. Aranesp (Amgen) is a re-
combinant human erythropoietin that has been
modified to contain additional N-glycosylation
sites to increase serum half life.Although Aranesp
is available in both an HSA-containing and HSA-
free formulation in the US, only the HSA-free for-
mulation, containing polysorbate 80, is approved
for use in Europe.
4 Discussion
Recombinant therapeutic proteins can be broadly
categorized into blood factors, anticoagulants,
growth factors, cytokines, hormones, vaccines,
therapeutic enzymes and monoclonal antibodies.
In each of these categories, evolution has occurred
in the manufacturing and engineering of these
products resulting in  better therapeutic outcomes,
such as enhanced safety,lower immunogenicity,in-
creased half-life, improved bioavailability and al-
ternative routes of administration.These enhance-
Table 2. Recommendations by regulatory agencies and physicians’ organizations for the avoidance of human or animal proteins in drug manufacturing
Organization Recommendation Reference
The European Medicines  “When manufacturers have a choice the use of materials from […]  [74]
Evaluation Agency (EMEA) non-animal origin is preferred”
Committee for Proprietary Medicinal  The European note of guidance: “when medicinal products prepared [75]
Products (CPMP- advisory to EMEA) from human blood or plasma are administered, infectious diseases due 
to the transmission of infective agents cannot be totally excluded. 
This also applies to pathogens of unknown nature…”
The Medical and Scientific Advisory Council  Encouraging manufacturers to “avoid using human and animal  [76]
of the National Hemophilia Foundation (US) proteins in manufacturing their products”
The UK Haemophilia Centre  Guidelines to choose “recombinant concentrates […] manufactured [77]
Doctors’ Organisation and formulated with the least addition of human or animal protein…”
The Association of Hemophilia  Guidelines for “the elimination of animal and human proteins as  [78]
Clinic Directors of Canada stabilizers in the final formulation, or as nutrients in the cell culture, 
or in any other part of the process, should be considered as a goal 
in terms of the quality of products”
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ments should have a positive impact on patient
compliance and consequently on treatment out-
comes.
The safety of biopharmaceuticals has come to
the forefront for both patients and health care
providers due to outbreaks of emerging pathogens,
most notably HIV, HCV, vCJD, WNV and SARS, in
multiple regions of the world [http://www.who.
int/whr/2007/whr07_en.pdf]. The risk of pathogen
transmission through the use of human- or animal-
derived raw materials in the manufacture of phar-
maceuticals was the major driver behind the devel-
opment of PF technology. Blood-derived products
were at a special risk of harboring infectious agents
and thus present the most important example of
the shift to  safe alternatives produced by PF man-
ufacturing technology. Patients with hemophilia
were at particularly high risk for infection by
blood-borne pathogens because they relied on
plasma-derived or plasma-containing clotting fac-
tor therapies. This excessively high risk was first
evidenced by the transmission of HIV-1 to approx-
imately halfthe hemophilia population prior tothe
availability of ascreening assay for that virus [83].
A number of measures have been implemented
in recent years to ensure the safety of plasma de-
rivatives. These measures include screening of
blood donors, rigorous testing of plasma pools, in-
corporation of virus inactivation or removal steps
into the manufacturing process and ultimately, the
development of recombinant products [83]. These
measures have greatly reduced the threat of
pathogen transmission, but some risk remains be-
cause a number of recombinant products still in-
corporate plasma-derived additives during manu-
facture [19].
Although tests are available to screen for most
known pathogens,no tests exist to screen the blood
supply for infectious agents such as prions. Prions
and parvovirus B19 may be markers for as yet
undiscovered or unrecognized blood-borne infec-
tious agents [MASAC#169].The risk from unknown
pathogens should not be neglected,as these agents
may appear in the blood supply in the future and
could have a significant impact on anyone receiv-
ing a therapy derived from blood or produced with
blood-derived additives.
Most recombinant therapeutic proteins are in-
jectables and many are used over long durations
for the treatment of chronic diseases,in which case
repeated infusions increase the cumulative risk to
the patient. To completely eliminate the potential
risk of transmission of any new or existing infec-
tions agent, recombinant therapeutic proteins
should be produced in cell lines in the absence of
human- or animal-derived proteins, processed
with dedicated pathogen removal and/or inactiva-
tion steps, rigorously tested for lipid- and non-
lipid-enveloped viruses,and packaged or stabilized
in the absence of human- or animal-derived pro-
teins.
The PF process often serves as a platform for
the development of more advanced versions of ex-
isting drugs. Some of these drugs are genetically
modified for greater efficacy, increased half-life, or
lower immunogenicity, while others are tailored to
be effective in specific groups of patients, or engi-
neered to be effectively administered through less
invasive routes. Erythropoeisis-stimulating agents,
which were introduced in the late 1980s for the
management of anemia in patients with chronic
kidney disease [84], serve as a good illustration of
the evolution of recombinant therapeutic protein
manufacturing. First, a recombinant product re-
placed its blood-derived predecessors. In the next
phase, a product with a longer half-life was devel-
oped (darbepoetin αor Aranesp).This product then
evolved through  conversion to an HSA-free for-
mulation [85], followed by  serum-free formula-
tions of Epoetin α (outside the US, Eprex; Ortho
Biotech) and Epoetin β (NeoRecormon; Roche).
Most recently, a PF, PEGylated recombinant ery-
thropoietin β with a longer half-life was developed
and licensed in Europe (Mircera; Roche).
Advances in the optimization of serum-free me-
dia for the production of mAbs have succeeded in
enhancing hybridoma productivity and product
quality as compared to traditional cell culture me-
dia supplemented with FBS [45, 65-67]. Nonethe-
less, eliminating animal-derived components from
media can significantly alter culture performance
as well as post-translational protein modifications.
The glycosylation pattern of an antibody molecule
can affect its structural integrity, thus influencing
both its biological function and its physicochemical
properties.Heterogeneity in glycosylation patterns
is evident in mAbs produced by hybridoma cells
grown in media with different serum content [86].
In addition to influencing pharmacokinetics,glyco-
sylation may influence both efficacy and safety,
particularly immunogenicity [87].
Other factors that can influence the molecular
integrity of a protein and affect its immunogenicity
profile are physical degradation events such as un-
folding, misfolding, fragmentation and aggregation
[58, 88]. Biopharmaceuticals may become exposed
to various conditions of stress, such as low pH or
heat, which can potentially result in protein mis-
folding and the formation of amyloid-like struc-
tures [62].The mechanisms by which different cul-
ture, formulation and storage conditions affect the
physical stability of proteins are an active area of
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research. Biopharmaceuticals require  monitoring
for potentially rare safety issues that might only be
seen in studies of a large number of patients over
an extended period of time. Thus, to ensure the
safety of new PF products,phase IV post-licensure
safety surveillance studies must be conducted to
monitor products for efficacy as well as for rare,ad-
verse events.
In reviewing the factors driving the develop-
ment of innovative solutions to the use of human-
and animal-derived products in the manufacture of
biopharmaceuticals,the question remains whether
regulatory agencies and industry in general are
prepared to actively embrace changes such as
adopting and/or mandating the use of a PF process
for all new or reformulated therapeutic proteins.
With the average cost of developing a biopharma-
ceutical product exceeding $1 billion [http://csdd.
tufts.edu],manufacturers should make every effort
to use the safest possible technologies,such as a PF
manufacturing process. Given that no major infec-
tious agent outbreaks have occurred in recent
years, a false sense of security may be in place, but
steps should be taken to avoid complacency. Such
issues need to be addressed now that PF technolo-
gy has matured and become more feasible,and this
should be accomplished prior to the next major
threat from a new, emerging pathogen.
Table 3. Selected list of approved recombinant therapeutic proteins produced in mammalian cell lines
Trade name Recombinant product Expression PF cell culture  PF formula- Year of
system medium?a) tion?a) approval
Activase Tissue plasminogen activator CHO cells No Yes 1987 (US)
Epogen/Procrit Erythropoietin (epoetin α) CHO cells No No 1989/1990 (US)
Recombinate Clotting factor VIII CHO cells No No 1992 (US)
1993 (EU)
Kogenate; Helixate Clotting factor VIII BHK cells No No 1993 (US)
2000 (EU)
Kogenate FS;  Clotting factor VIII  BHK cells No Yes 1993 (US)
Helixate FS (sucrose formulation) 2000 (EU)
Cerezyme β-glucocerebrosidase CHO cells No Yes 1994 (US)
1997 (EU)
Avonex IFN-β-1a CHO cells No Yes, in new 1996 (US)
formulation (EU 2003) 1997 (EU)
Benefix Clotting factor IX CHO cells Yes Yes 1997 (US)
1997 (EU)
Rituxan (US)/  Anti-CD20 chimeric mAb CHO cells No Yes 1997 (US)
Mabthera (EU) 1998 (EU)
Gonal-f Follicle stimulating hormone  CHO cells Yes, in new formulation  Yes 1997 (US)
(follitropin α) (EU) 1995  (EU)
No (US)
Simulect Anti-IL2 receptor- RFT5 (Murine  No Yes 1998 (US)
α chimeric mAb hybridoma) cells 1998 (EU)
Remicade Anti-TNF α chimeric mAb SP2/0 (Murine  No Yes 1998 (US)
hybridoma) cells 1999 (EU)
Herceptin Anti-HER2 humanized mAb CHO cells Yes Yes 1998 (US)
2000 (EU)
Enbrel TNF α receptor –  CHO cells No Yes 1998(US)
IgG fusion protein 2000 (EU)
Thyrogen Thyrotropin α CHO cells No Yes 1998(US)
2000 (EU)
Novoseven Clotting factor VII a BHK cells No Yes 1999(US)
1996 (EU)
Ovidrel or Human chorionic  CHO cells No Yes 2000 (US)
Ovitrelle gonadotropin α 2001 (EU)
ReFacto B domain-deleted  CHO cells No Yes 2000 (US)
clotting factor VIII  1999 (EU)
TNKase Tissue plasminogen activator CHO cells No Yes 2000 (US)
Aranesp Darbepoetin α CHO cells No No (US) 2001 (US)
Yes (EU) 2001 (EU)
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Table 3. Continued
Trade name Recombinant product Expression PF cell culture  PF formula- Year of
system medium?a) tion?a) approval
Xigris Activated protein C  HEK293 (Human) cell line No Nob) 2001 (US)
(antithrombotic) 2002 (EU)
Osigraft (Osteo- Osteogenic protein-1:  CHO cells No No 2001 (US)
genic protein 1) bone morphogenetic protein-7 2001 (EU)
Rebif IFN-β-1a CHO cells No No 2002(US)
1998 (EU)
Humira Anti-TNF α human mAb CHO cells Yes Yes 2002 (US)
2003 (EU)
Amevive LFA-3-IgG fragment fusion protein CHO cells No Yes 2003 (US)
Fabrazyme α-galactosidase A CHO cells No Yes 2003 (US)
2001 (EU)
Aldurazyme Laronidase (α-L-iduronidase) CHO cells No No 2003 (US)
2003 (EU)
Xolair Anti-IgE humanized mAb CHO cells Yes Yes 2003 (US)
2005 (EU)
Advate Clotting factor VIII (plasma/ CHO cells Yes Yes 2003 (US)
albumin free) 2004 (EU)
Raptiva Anti-CD11a humanized mAb CHO cells No Yes 2003 (US)
2004 (EU)
Avastin Anti-VEGF humanized mAb CHO cells Yes Yes 2004 (US)
2005 (EU)
Luveris Luteinizing hormone CHO cells No Yes 2004 (US)
2000 (EU)
Naglazyme N-acetylgalactosamine-4-sulfatase CHO cells No Yes 2005 (US)
2006 (EU)
Orencia Ig-CTLA4 fusion (antirheumatic) CHO cells Yes Yes 2005 (US)
2007 (EU)
Myozyme Acid α-glucosidase CHO cells No Yes 2006 (US)
2006 (EU)
Vectibix Anti-EGFR human mAb CHO cells Yes Yes 2006 (US)
2007 (EU)
Soliris Anti-C5 (Complement protein)  NS0 (Murine  No Yes 2007 (US)
humanized mAb myeloma) cells 2007 (EU)
Mircera Methoxy polyethylene glycol- CHO cells Yes Yes 2007 (US)
epoetin β 2007 (EU)
Rebif New  rh IFN-β-1a CHO cells Yes Yes 2007 (EU)
Formulation
Optaflu Cell-based seasonal influenza vaccine MDCK cells Yes Yes 2007 (EU)
Recothrom Topical human thrombin CHO cells Yes Yes 2008 (US)
Xyntha B domain-deleted clotting factor VIII CHO cells Yes Yes 2008 (US)
a) To the extent that information is disclosed by the manufacturer and available publicly on the FDA and EMEA websites.
b) Though final formulation is animal-free, bovine thrombin is used to activate the zymogen.
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